The number of biosimilars launching in 2023 will spike as legal challenges around patent infringement are finally expiring. That will only exacerbate the problem of biosim
The article below should be a learning moment for the specialty pharmacy industry. It is all about going digital…. but it does not get lost in techno
This week the FDA approved a new ORAL specialty drug, Skyclarys (omaveloxolone) from Reata Pharmaceutical, indicated for the treatment of Friedreich’s Ataxia in adults and
The FDA recently approved a new antihemophilic factor (recombinant) for Hemophilia A, Altuviiio (Fc-VWFXTEN fusion protein-ehtl) from Sanofi. It was approved for prophylaxis, on-demand treatment of
The article below speaks to a variety of inefficiencies in Specialty Pharmacy Information Technology. What an opportunity to create a new acronym…. SPIT. The article makes the case that SPIT
Just about every specialty pharmacy has already obtained specialty pharmacy accreditation if they want to be a serious player in the SP market. The most serious
Clinical Trials….. are you ready to give even a five minute standup presentation to a group of new employees to orient them to this integral, yet
The FDA recently approved a new ORAL therapy, Jaypirca (pirtobrutinib) from Eli Lilly and Company, indicated for mantle cell lymphoma (MCL) after at least two
The day has finally arrived. The day when a biosimilar to Humira finally hits the market. A total of 40 biosimilars have been approved since
Acronyms….. they seem to be everywhere….. especially in healthcare. One acronym that has surfaced in the specialty pharmacy world is MIP. Scratching your head on what that
